Concurrent increases in post-pacing action potential duration and contractility predict occurrence of ventricular arrhythmia

Pflugers Arch. 2020 Dec;472(12):1783-1791. doi: 10.1007/s00424-020-02445-7. Epub 2020 Aug 14.

Abstract

Excitation-contraction coupling from the integration of action potential duration (APD) and muscle contractility plays an important role in arrhythmogenesis. We aimed to determine whether distinctive excitation-contraction coupling contributes to the genesis of ventricular tachycardias (VTs). Action potential (AP) and mechanical activity were simultaneously recorded under electrical pacing (cycle lengths from 1000 to 100 ms) in the tissue model created from isolated rabbit right ventricular outflow tracts treated with NS 5806 (10 μM, transient outward potassium current enhancer), pinacidil (2 μM, ATP-sensitive potassium channel opener), and pilsicainide (5 μM, sodium channel blocker). There were 15 (9.9%) inducible VT episodes (group 1) and 136 (90.1%) non-inducible VT episodes (group 2) in our tissue model. Group 1 had greater post-pacing increases of the first occurrence of AP at 90% repolarization (ΔAPD90, p < 0.001) and contractility (ΔContractility, p = 0.003) compared with group 2. Triggered VT episodes were common (72.7%) in cases with a ΔAPD90 > 15% and a ΔContractility > 270%, but were undetectable in those with a ΔAPD90 < 15% and a ΔContractility < 270%. In those with pacing-induced VTs, KB-R7943 (10 μM, a Na+-Ca2+ exchanger inhibitor, NCX inhibitor) significantly reduced the occurrence of VTs from 100.0 to 20.0% (15/15 to 3/15 episodes, p < 0.001). Concurrent increases in both post-pacing APD and contractility resulted in the occurrence of ventricular arrhythmias. NCX inhibition may be a potential therapeutic strategy for ventricular arrhythmias.

Keywords: Action potential depolarization; Contractility; Na+–Ca2+ exchanger inhibitor; Ventricular arrhythmias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials*
  • Animals
  • Anti-Arrhythmia Agents / pharmacology
  • Heart / drug effects
  • Heart / physiopathology
  • Heart Rate
  • Lidocaine / analogs & derivatives
  • Lidocaine / pharmacology
  • Male
  • Myocardial Contraction*
  • Phenylurea Compounds / pharmacology
  • Pinacidil / pharmacology
  • Rabbits
  • Sodium Channel Blockers / pharmacology
  • Tachycardia, Ventricular / metabolism
  • Tachycardia, Ventricular / physiopathology*
  • Tetrazoles / pharmacology

Substances

  • 1-(3,5-bis-trifluoromethylphenyl)-3-(2,4-dibromo-6-(1H-tetrazol-5-yl)phenyl)urea
  • Anti-Arrhythmia Agents
  • Phenylurea Compounds
  • Sodium Channel Blockers
  • Tetrazoles
  • Pinacidil
  • Lidocaine
  • pilsicainide